Published in Cancer Weekly, March 23rd, 2004
MDM2 is the target of Hybridon's second-generation antisense drug candidate GEM240.
The paper, titled "MDM2 is a Negative Regulator of p21waf1/cip1, Independent of p53" and published in the February 2004 Journal of Biological Chemistry, is co-authored by Ruiwen Zhang, Zhuo Zhang, Hui Wang, Mao Li, and Xinbin Chen from the University of Alabama at Birmingham (Alabama) (UAB), and Sudhir Agrawal,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.